drugset / Trial / NCT02133079

Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

NCT02133079

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and Pancreatic Adenocarcinoma

Timeline

Start
2012-03
Primary completion
2016-11
Completion
2019-11

Drugs

EvaluationDrugModalityDoseRoute
Subject vitespen Vaccine